(Q30485533)

English

Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

1 reference

based on heuristic

inferred from title

human pregnancy

1 reference

based on heuristic

inferred from title

pregnant person

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

health professional

1 reference

based on heuristic

inferred from title

pertussis vaccine

1 reference

based on heuristic

inferred from title

object named as

Miriam Levi

4

0 references

5

object named as

Paolo Bonanni

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

author name string

Angela Bechini

1

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

Emilia Tiscione

2

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

Sara Boccalini

3

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

language of work or name

0 references

publication date

15 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

5179-5190

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

Duration of immunity against pertussis after natural infection or vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Whooping cough: the current scene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Acellular vaccines for preventing whooping cough in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Development of a pertussis component vaccine in Japan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

The present and future control of pertussis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

The reemergence of pertussis and infant deaths: is it time to immunize pregnant women?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Changing epidemiology and emerging risk groups for pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

The changing age and seasonal profile of pertussis in Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Epidemiology of pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis: an old disease in new clothes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis: should we improve intensive care management or vaccination strategies?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Prevention of Pertussis Among Adolescents: Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Recent developments in pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Resurgence of pertussis in Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Global, regional, and national causes of child mortality in 2008: a systematic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Public health perspectives on the rising incidence of pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis vaccination for adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Bordetella pertussis strains with increased toxin production associated with pertussis resurgence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Infant pertussis: who was the source?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Transmission of Bordetella pertussis to young infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Prospective Multinational Study of Pertussis Infection in Hospitalized Infants and Their Household Contacts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis disease in new mothers: effect on young infants and strategies for prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

A "new age" in pertussis prevention new opportunities through adult vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Nosocomial pertussis in healthcare workers from a pediatric emergency unit in France

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

A pertussis outbreak in a Wisconsin nursing home.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Successful control of a pertussis outbreak in a university children's hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Outbreak of pertussis among healthcare workers in a hospital surgical unit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Measures to control an outbreak of pertussis in a neonatal intermediate care nursery after exposure to a healthcare worker

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Vaccines for pertussis and influenza: recommendations for use in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Vaccines: correlates of vaccine-induced immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

How to make sense of pertussis immunogenicity data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Acellular pertussis vaccines for adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Acellular pertussis vaccine safety and efficacy in children, adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Immunity to pertussis 5 years after booster immunization during adolescence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Efficacy of an acellular pertussis vaccine among adolescents and adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis vaccine effectiveness after mass immunization of high school students in Australia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Early Impact of the US Tdap vaccination program on pertussis trends.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Maternal vaccination against pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Role of maternal pertussis antibodies in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

[Antibodies against vaccine-preventable diseases in pregnant women and their offspring. Diphtheria, pertussis, tetanus]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Simultaneous immunization of newborn infants against diphtheria, tetanus, and pertussis; production of antibodies and duration of antibody levels in an eastern metropolitan area

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Effect of a Prepregnancy Pertussis Booster Dose on Maternal Antibody Titers in Young Infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Natural history of pertussis antibody in the infant and effect on vaccine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Pertussis immunization in a high-risk postpartum population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Implementation of cocooning against pertussis in a high-risk population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Vaccination in the neonatal period and early infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Neonatal and early life vaccinology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Booster vaccination after neonatal priming with acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

[Vaccination coverage among health care workers in the pediatric emergency and intensive care department of Edouard Herriot hospital in 2007, against influenza, pertussis, varicella, and measles]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Tetanus, diphtheria, and acellular pertussis vaccine: a position statement of the Society for Adolescent Medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

The case for maternal vaccination against pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Immunogenicity of group A and group C meningococcal polysaccharides in human infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Immune Response of Human Infants to Polysaccharide Vaccines of Groups A and C Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.005

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.06.005

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30485533&oldid=1954426548"